Mammaglobin-A precursor (83-92)

Mammaglobin-A precursor (83-92) is a synthetic peptide fragment derived from the mammaglobin-A protein, a member of the secretoglobin family that is notably overexpressed in mammary tissue. This peptide encompasses amino acid residues 83 to 92 of the precursor protein, representing a region of interest for researchers investigating breast tissue-specific biomarkers and molecular mechanisms underlying glandular differentiation. Its defined sequence and biochemical properties make it a valuable tool for probing the structural and functional roles of mammaglobin-A in cellular processes, as well as for applications in peptide-based assay development and molecular recognition studies.

Peptide biomarker research: The 83-92 fragment of the mammaglobin-A precursor is frequently utilized in studies aiming to elucidate the role of mammaglobin-A as a tissue-specific biomarker, particularly in the context of breast tissue. Researchers leverage this peptide to generate and validate antibody reagents for immunodetection assays, enabling the selective identification and quantification of mammaglobin-A expression in cell lysates and tissue samples. Its sequence specificity supports high-fidelity studies of protein localization and abundance, contributing to a deeper understanding of tissue differentiation and pathology at the molecular level.

Immunological assay development: As a well-characterized epitope, the peptide serves as an ideal antigen for the development and optimization of immunoassays such as enzyme-linked immunosorbent assays (ELISA) and Western blotting protocols. By incorporating the 83-92 region into assay platforms, scientists can assess the sensitivity and specificity of antibody reagents, calibrate detection systems, and standardize experimental workflows. This application is particularly valuable for laboratories seeking to improve the reliability and reproducibility of mammaglobin-A detection in research settings.

Epitope mapping and antibody characterization: The defined sequence of this peptide fragment enables detailed epitope mapping studies, which are essential for characterizing the binding sites of monoclonal and polyclonal antibodies directed against mammaglobin-A. By using the 83-92 peptide in competitive binding assays and structural analyses, researchers can elucidate the molecular interactions that govern antibody-antigen recognition, informing the design of more selective and high-affinity immunoreagents.

Peptide-based affinity purification: The unique biochemical features of the mammaglobin-A precursor (83-92) peptide allow its use as a ligand in affinity purification protocols. Immobilized on chromatographic matrices, it can selectively capture antibodies or binding proteins specific to the corresponding mammaglobin-A epitope from complex biological mixtures. This approach facilitates the isolation of high-purity immunoreagents for downstream applications and enhances the efficiency of antibody production workflows.

Functional studies of protein-protein interactions: The 83-92 peptide segment provides a model system for dissecting the molecular interactions between mammaglobin-A and its potential binding partners. By incorporating the peptide into in vitro binding assays or structural studies, scientists can investigate the determinants of protein-protein recognition, explore the functional implications of sequence motifs, and gain mechanistic insights into the biological roles of secretoglobin family members in mammary gland biology. This application supports the broader effort to map interaction networks and regulatory pathways involving mammaglobin-A and related proteins.

1. TMEM16F and dynamins control expansive plasma membrane reservoirs

2. Emu oil in combination with other active ingredients for treating skin imperfections

3. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

4. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

5. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis